

Alaska Vaccine-Preventable Disease Surveillance Report

1st Quarter 2024 (January-March)

The purpose of this report is to provide timely vaccine-preventable disease information to health care providers and other stakeholders for situational awareness.

Summary of Reported Cases of Select Vaccine-Preventable Disease, Alaska

	Anch	Mat-Su	Gulf Coast	Interior	Northern	Southeast	South west	2024 Q1 (Jan-Mar) Total *†	2024 YTD Total	2023 Total *†	2022 Total *†
<i>Haemophilus influenzae</i> , invasive disease	1	1	0	2	0	1	0	5	5	25	36
Hepatitis A	0	0	0	1	0	0	0	0	1	0	2
Hepatitis B, acute	0	0	0	1	0	0	0	0	1	1	1
Measles	0	0	0	0	0	0	0	0	0	0	0
Meningococcal invasive disease	0	0	0	0	0	0	0	0	0	2	0
Mumps	0	0	0	0	0	0	0	0	0	1	1
Pertussis	3	6	7	4	0	0	1	21	21	24	2
Pneumococcal invasive disease	24	6	4	10	2	6	8	60	60	230	250
Rubella	0	0	0	0	0	0	0	0	0	0	0
Tetanus	0	0	0	0	0	0	0	0	0	0	0

*Counts are provisional and may be updated.

†Includes confirmed and probable cases.

Haemophilus influenzae, invasive disease

During the January-March 2024 period, 5 cases were reported to the Alaska Section of Epidemiology (SOE):

- 5/5 (100%) of the cases were confirmed by culture or PCR from normally sterile sites
- Isolate serotypes: 2 Hib, 1 Hif, 1 non-typeable, and 1 unknown
- One of the isolates serotyped from cases involving children <5 years of age was vaccine preventable

Age Group (years)	No. Cases	No. Cases Hib Vax Up-to-Date (UTD) [±]
<2	1 (20%)	0
2-4	0	0
≥5	4 (80%)	N/A

Pertussis

During the January-March 2024 period, 21 cases were reported to the SOE:

- 16 cases were laboratory-confirmed by PCR, and 5 were epi-linked to laboratory-confirmed cases

Age Group (years)	No. Cases	No. Cases Pertussis Vax Up-to-Date UTD [±]
<15	14 (67%)	5 (35%)
15-19	2 (1%)	1 (50%)
20-29	3 (14%)	2 (67%)
30-39	1 (0.5%)	0
40-49	0	0
50-59	0	0
≥60	1 (0.5%)	0



Invasive pneumococcal disease

During the January-March 2024 period, 60 cases were reported to the SOE:

- All cases were confirmed by either PCR or culture isolation of *Streptococcus pneumoniae* from a normally sterile body site

Age Group (years)	No. Cases
<2	4 (6%)
2-4	3 (5%)
5-18	1 (2%)
19-64	36 (60%)
≥65	16 (27%)

*Based upon the Advisory Committee on Immunization Practice's routine age-appropriate immunization recommendations for children and adults who are not at increased risk for this disease.

VPD Updates and Reminders

- **Measles:** For the latest surveillance data from CDC visit: <http://www.cdc.gov/measles/cases-outbreaks.html>
- **Mumps:** For the latest surveillance data from CDC visit: <http://www.cdc.gov/mumps/outbreaks.html>
- Conditions reportable to public health in Alaska, available at: <https://health.alaska.gov/dph/Epi/Pages/pubs/conditions/default.aspx>
- Recommended immunizations for children and adults, and administration schedules: <https://health.alaska.gov/dph/Epi/iz/Pages/parents.aspx>
- Cases are defined according to national standards: <https://ndc.services.cdc.gov/>
- **Varicella:** [Effective 9/3/2023, Alaska Division of Public Health reporting requirements were updated.](#) Individual suspected or confirmed varicella (chickenpox) infections are no longer reportable to public health by laboratories or health care providers. Varicella deaths must be reported by health care providers (7 AAC 27.005)

VPD Surveillance Coordinator Contact: Kristen Moore 907-269-8054, Email: Kristen.Moore@alaska.gov

